|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:First_Gen_Corporation
|
|
gptkbp:acquisition
|
gptkb:Zymeworks_Inc.
gptkb:Alder_Bio_Pharmaceuticals
|
|
gptkbp:awards
|
Best Places to Work
Top 100 Biotech Companies
|
|
gptkbp:ceo
|
gptkb:Dr._John_C._Martin
|
|
gptkbp:clinical_trial
|
Phase 3 trials
Phase 1 trials
Phase 2 trials
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Stanford_University
gptkb:University_of_California
|
|
gptkbp:community_involvement
|
gptkb:charity
educational initiatives
volunteer programs
|
|
gptkbp:employees
|
over 500
|
|
gptkbp:focus
|
genetic medicine
|
|
gptkbp:founded
|
gptkb:1998
|
|
gptkbp:founder
|
gptkb:Dr._John_C._Martin
|
|
gptkbp:headquarters
|
gptkb:South_San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
FGEN
|
|
gptkbp:invention
|
over 100 patents
biotechnology patents
genetic engineering patents
|
|
gptkbp:investment
|
Venture capital firms
|
|
gptkbp:language_of_instruction
|
multiple drug candidates
clinical candidates
preclinical candidates
|
|
gptkbp:mission
|
improve patient lives
|
|
gptkbp:partnerships
|
gptkb:temple
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:products
|
gptkb:Zymeworks
gptkb:Fusilev
|
|
gptkbp:research_areas
|
oncology
autoimmune diseases
infectious diseases
|
|
gptkbp:research_focus
|
gptkb:physicist
gptkb:drug
biologics
|
|
gptkbp:revenue
|
$200 million (2022)
|
|
gptkbp:subsidiary
|
F Gen Biopharma
F Gen Therapeutics
|
|
gptkbp:sustainability
|
sustainable practices
green initiatives
environmental responsibility
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:values
|
gptkb:collaboration
innovation
integrity
excellence
|
|
gptkbp:vision
|
leading in genetic medicine
|
|
gptkbp:website
|
www.fgen.com
|